Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Low-dose Naltrexone for Pain and Quality of Life in Vulvodynia
NCT05955313Phase 2Recruiting
- Sponsor
- Medical University of Lublin
- Start
- May 2023
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, triple-blind trial in vulvodynia comparing Naltrexone with Placebo (2 arms). Primary endpoints: Change in pain intensity at 4 months, Change in type and severity of pain at 4 months and 2 more. Started May 2023; status: recruiting.
02
Drugs
naltrexone
03
Conditions
vulvodynia
Beyond the preview
Go deeper on NCT05955313.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05955313.